Epigenetic markers of ovarian cancer

Advances in Experimental Medicine and Biology

Volumn 622, Issue , 2008, Pages 35-51

  Barton, Caroline A ^a   Clark, Susan J ^a   Hacker, Neville F ^a   O'Brien, Philippa M ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; DEATH ASSOCIATED PROTEIN KINASE; DNA; FANCONI ANEMIA GROUP F PROTEIN; PROTEIN DNAJ; PROTEIN MLH1; PROTEIN P14; PROTEIN P16; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A;

ACETYLATION; BASE MISPAIRING; CPG ISLAND; DNA METHYLATION; DNA SEQUENCE; EARLY DIAGNOSIS; EPIGENETICS; FEMALE; GENE AMPLIFICATION; GENE DELETION; GENE MUTATION; GENETIC MARKER; HUMAN; HUMAN CELL; HUMAN TISSUE; MORTALITY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 84934435040     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-0-387-68969-2_4     Document Type: Review

References (133)

1. Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R.C., Ghafoor, A., Feuer, E.J., and Thun, M.J. (2005) Cancer statistics, 2005. CA Cancer J Clin 55, 10-30.
2. Barnholtz-Sloan, J.S., Schwartz, A.G., Qureshi, F., Jacques, S., Malone, J., and Munkarah, A.R. (2003) Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol 189, 1120-1127.
3. Wolffe, A.P., and Matzke, M.A. (1999) Epigenetics: regulation through repression. Science 286, 481-486.
4. Jones, P.A., and Baylin, S.B. (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3, 415-428.
5. Bird, A. (1986) CpG-rich islands and the function of DNA methylation. Nature 321, 209-213.
6. Gardiner-Garden, M., and Frommer, M. (1987) CpG islands in vertebrate genomes. J Mol Biol 196, 261-282.
7. Clark, S.J., and Melki, J. (2002) DNA methylation and gene silencing in cancer: which is the guilty party? Oncogene 21, 5380-5387.
8. Lund, A.H., and van Lohuizen, M. (2004) Epigenetics and cancer. Genes Dev 18, 2315-2335.
9. Stirzaker, C., Song, J.Z., Davidson, B., and Clark, S.J. (2004) Transcriptional gene silencing promotes DNA hypermethylation through a sequential change in chromatin modifications in cancer cells. Cancer Res 64, 3871-3877.
10. Ehrlich, M. (2002) DNA methylation in cancer: too much, but also too little. Oncogene 21, 5400-5413.
11. Bird, A. (1996) The relationship of DNA methylation to cancer. Cancer Surv 28, 87-101.
12. Egger, G., Liang, G., Aparicio, A., and Jones, P.A. (2004) Epigenetics in human disease and prospects for epigenetic therapy. Nature 429, 457-463.
13. Esteller, M. (2002) CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 21, 5427-5440.
14. Herman, J.G., and Baylin, S.B. (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349, 2042-2054.
15. Jones, P.A., and Laird, P.W. (1999) Cancer epigenetics comes of age. Nat Genet 21, 163-167.
16. Feinberg, A.P., and Tycko, B. (2004) The history of cancer epigenetics. Nat Rev Cancer 4, 143-153.
17. Walsh, C.P., Chaillet, J.R., and Bestor, T.H. (1998) Transcription of IAP endogenous retroviruses is constrained by cytosine methylation. Nat Genet 20, 116-117.
18. Alves, G., Tatro, A., and Fanning, T. (1996) Differential methylation of human LINE-1 retrotransposons in malignant cells. Gene 176, 39-44.
19. Costello, J.F., and Plass, C. (2001) Methylation matters. J Med Genet 38, 285-303.
20. Eden, A., Gaudet, F., Waghmare, A., and Jaenisch, R. (2003) Chromosomal instability and tumors promoted by DNA hypomethylation. Science 300, 455.
21. Gaudet, F., Hodgson, J.G., Eden, A., Jackson-Grusby, L., Dausman, J., Gray, J.W., Leonhardt, H., and Jaenisch, R. (2003) Induction of tumors in mice by genomic hypomethylation. Science 300, 489-492.
22. Tuck-Muller, C.M., Narayan, A., Tsien, F., Smeets, D.F., Sawyer, J., Fiala, E.S., Sohn, O.S., and Ehrlich, M. (2000) DNA hypomethylation and unusual chromosome instability in cell lines from ICF syndrome patients. Cytogenet Cell Genet 89, 121-128.
23. Ahluwalia, A., Yan, P., Hurteau, J.A., Bigsby, R.M., Jung, S.H., Huang, T.H., and Nephew, K.P. (2001) DNA methylation and ovarian cancer. I. Analysis of CpG island hypermethylation in human ovarian cancer using differential methylation hybridization. Gynecol Oncol 82, 261-268.
24. Strathdee, G., Appleton, K., Illand, M., Millan, D.W., Sargent, J., Paul, J., and Brown, R. (2001) Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am J Pathol 158, 1121-1127.
25. Grady, W.M. (2005) Epigenetic events in the colorectum and in colon cancer. Biochem Soc Trans 33, 684-688.
26. Costello, J.F., Fruhwald, M.C., Smiraglia, D.J., Rush, L.J., Robertson, G.P., Gao, X., Wright, F.A., Feramisco, J.D., Peltomaki, P., Lang, J.C., Schuller, D.E., Yu, L., Bloomfield, C.D., Caligiuri, M.A., Yates, A., Nishikawa, R., Su Huang, H., Petrelli, N.J., Zhang, X., O'Dorisio, M.S., Held, W.A., Cavenee, W.K., and Plass, C. (2000) Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 24, 132-138.
27. Esteller, M., and Herman, J.G. (2002) Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol 196, 1-7.
28. Melki, J.R., and Clark, S.J. (2002) DNA methylation changes in leukaemia. Semin Cancer Biol 12, 347-357.
29. Melki, J.R., Vincent, P.C., and Clark, S.J. (1999) Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia. Cancer Res 59, 3730-3740.
30. Esteller, M., Corn, P.G., Baylin, S.B., and Herman, J.G. (2001) A gene hypermethylation profile of human cancer. Cancer Res 61, 3225-3229.
31. Esteller, M., Silva, J.M., Dominguez, G., Bonilla, F., Matias-Guiu, X., Lerma, E., Bussaglia, E., Prat, J., Harkes, I.C., Repasky, E.A., Gabrielson, E., Schutte, M., Baylin, S.B., and Herman, J.G. (2000) Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 92, 564-569.
32. Baldwin, R.L., Nemeth, E., Tran, H., Shvartsman, H., Cass, I., Narod, S., and Karlan, B.Y. (2000) BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res 60, 5329-5333.
33. Buller, R.E., Shahin, M.S., Geisler, J.P., Zogg, M., De Young, B.R., and Davis, C.S. (2002) Failure of BRCA1 dysfunction to alter ovarian cancer survival. Clin Cancer Res 8, 1196-1202.
34. Catteau, A., Harris, W.H., Xu, C.F., and Solomon, E. (1999) Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene 18, 1957-1965.
35. Geisler, J.P., Hatterman-Zogg, M.A., Rathe, J.A., and Buller, R.E. (2002) Frequency of BRCA1 dysfunction in ovarian cancer. J Natl Cancer Inst 94, 61-67.
36. Ibanez de Caceres, I., Battagli, C., Esteller, M., Herman, J.G., Dulaimi, E., Edelson, M.I., Bergman, C., Ehya, H., Eisenberg, B.L., and Cairns, P. (2004) Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res 64, 6476-6481.
37. Rathi, A., Virmani, A.K., Schorge, J.O., Elias, K.J., Maruyama, R., Minna, J.D., Mok, S.C., Girard, L., Fishman, D.A., and Gazdar, A.F. (2002) Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin Cancer Res 8, 3324-3331.
38. Teodoridis, J.M., Hall, J., Marsh, S., Kannall, H.D., Smyth, C., Curto, J., Siddiqui, N., Gabra, H., McLeod, H.L., Strathdee, G., and Brown, R. (2005) CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 65, 8961-8967.
39. Chan, K.Y., Ozcelik, H., Cheung, A.N., Ngan, H.Y., and Khoo, U.S. (2002) Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer. Cancer Res 62, 4151-4156.
40. Wilcox, C.B., Baysal, B.E., Gallion, H.H., Strange, M.A., and DeLoia, J.A. (2005) High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors. Cancer Genet Cytogenet 159, 114-122.
41. Futreal, P.A., Liu, Q., Shattuck-Eidens, D., Cochran, C., Harshman, K., Tavtigian, S., Bennett, L.M., Haugen-Strano, A., Swensen, J., Miki, Y., and et al. (1994) BRCA1 mutations in primary breast and ovarian carcinomas. Science 266, 120-122.
42. Yu, Y., Xu, F., Peng, H., Fang, X., Zhao, S., Li, Y., Cuevas, B., Kuo, W.L., Gray, J.W., Siciliano, M., Mills, G.B., and Bast, R.C., Jr. (1999) NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci USA 96, 214-219.
43. Yuan, J., Luo, R.Z., Fujii, S., Wang, L., Hu, W., Andreeff, M., Pan, Y., Kadota, M., Oshimura, M., Sahin, A.A., Issa, J.P., Bast, R.C., Jr., and Yu, Y. (2003) Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers. Cancer Res 63, 4174-4180.
44. Yu, Y., Luo, R., Lu, Z., Wei Feng, W., Badgwell, D., Issa, J.P., Rosen, D.G., Liu, J., and Bast, R.C., Jr. (2005) Biochemistry and biology of ARHI (DIRAS3), an imprinted tumor suppressor gene whose expression is lost in ovarian and breast cancers. Methods Enzymol 407, 455-468.
45. Kwong, J., Lee, J.Y., Wong, K.K., Zhou, X., Wong, D.T., Lo, K.W., Welch, W.R., Berkowitz, R.S., and Mok, S.C. (2006) Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer. Neoplasia 8, 268-278.
46. Campbell, I.G., Foulkes, W.D., Beynon, G., Davis, M., and Englefield, P. (1995) LOH and mutation analysis of CDKN2 in primary human ovarian cancers. Int J Cancer 63, 222-225.
47. Schultz, D.C., Vanderveer, L., Buetow, K.H., Boente, M.P., Ozols, R.F., Hamilton, T.C., and Godwin, A.K. (1995) Characterization of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2. Cancer Res 55, 2150-2157.
48. Furonaka, O., Takeshima, Y., Awaya, H., Ishida, H., Kohno, N., and Inai, K. (2004) Aberrant methylation of p14(ARF), p15(INK4b) and p16(INK4a) genes and location of the primary site in pulmonary squamous cell carcinoma. Pathol Int 54, 549-555.
49. Wong, T.S., Man, M.W., Lam, A.K., Wei, W.I., Kwong, Y.L., and Yuen, A.P. (2003) The study of p16 and p15 gene methylation in head and neck squamous cell carcinoma and their quantitative evaluation in plasma by real-time PCR. Eur J Cancer 39, 1881-1887.
50. Brown, I., Milner, B.J., Rooney, P.H., and Haites, N.E. (2001) Inactivation of the p16INK4Agene by methylation is not a frequent event in sporadic ovarian carcinoma. Oncol Rep 8, 1359-1362.
51. Hashiguchi, Y., Tsuda, H., Yamamoto, K., Inoue, T., Ishiko, O., and Ogita, S. (2001) Combined analysis of p53 and RB pathways in epithelial ovarian cancer. Hum Pathol 32, 988-996.
52. Katsaros, D., Cho, W., Singal, R., Fracchioli, S., Rigault De La Longrais, I.A., Arisio, R., Massobrio, M., Smith, M., Zheng, W., Glass, J., and Yu, H. (2004) Methylation of tumor suppressor gene p16 and prognosis of epithelial ovarian cancer. Gynecol Oncol 94, 685-692.
53. Makarla, P.B., Saboorian, M.H., Ashfaq, R., Toyooka, K.O., Toyooka, S., Minna, J.D., Gazdar, A.F., and Schorge, J.O. (2005) Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin Cancer Res 11, 5365-5369.
54. Niederacher, D., Yan, H.Y., An, H.X., Bender, H.G., and Beckmann, M.W. (1999) CDKN2Agene inactivation in epithelial sporadic ovarian cancer. Br J Cancer 80, 1920-1926.
55. Sellar, G.C., Watt, K.P., Rabiasz, G.J., Stronach, E.A., Li, L., Miller, E.P., Massie, C.E., Miller, J., Contreras-Moreira, B., Scott, D., Brown, I., Williams, A.R., Bates, P.A., Smyth, J. F., and Gabra, H. (2003) OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. Nat Genet 34, 337-343.
56. Zhang, J., Ye, F., Chen, H.Z., Ye, D.F., Lu, W.G., and Xie, X. (2006) Deletion of OPCMLgene and promoter methylation in ovarian epithelial carcinoma. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 28, 173-177.
57. Takada, T., Yagi, Y., Maekita, T., Imura, M., Nakagawa, S., Tsao, S.W., Miyamoto, K., Yoshino, O., Yasugi, T., Taketani, Y., and Ushijima, T. (2004) Methylation-associated silencing of the Wnt antagonist SFRP1 gene in human ovarian cancers. Cancer Sci 95, 741-744.
58. Yanaihara, N., Nishioka, M., Kohno, T., Otsuka, A., Okamoto, A., Ochiai, K., Tanaka, T., and Yokota, J. (2004) Reduced expression of MYO18B, a candidate tumor-suppressor gene on chromosome arm 22q, in ovarian cancer. Int J Cancer 112, 150-154.
59. Horak, P., Pils, D., Haller, G., Pribill, I., Roessler, M., Tomek, S., Horvat, R., Zeillinger, R., Zielinski, C., and Krainer, M. (2005) Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer. Mol Cancer Res 3, 335-343.
60. Pfeifer, G.P., Yoon, J.H., Liu, L., Tommasi, S., Wilczynski, S.P., and Dammann, R. (2002) Methylation of the RASSF1A gene in human cancers. Biol Chem 383, 907-914.
61. Agathanggelou, A., Honorio, S., Macartney, D.P., Martinez, A., Dallol, A., Rader, J., Fullwood, P., Chauhan, A., Walker, R., Shaw, J.A., Hosoe, S., Lerman, M.I., Minna, J.D., Maher, E.R., and Latif, F. (2001) Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene 20, 1509-1518.
62. Yoon, J.H., Dammann, R., and Pfeifer, G.P. (2001) Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas. Int J Cancer 94, 212-217.
63. Chang, Y.S., Wang, L., Liu, D., Mao, L., Hong, W.K., Khuri, F.R., and Lee, H.Y. (2002) Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Clin Cancer Res 8, 3669-3675.
64. Hanafusa, T., Yumoto, Y., Nouso, K., Nakatsukasa, H., Onishi, T., Fujikawa, T., Taniyama, M., Nakamura, S., Uemura, M., Takuma, Y., Yumoto, E., Higashi, T., and Tsuji, T. (2002) Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma. Cancer Lett 176, 149-158.
65. Wiley, A., Katsaros, D., Fracchioli, S., and Yu, H. (2006) Methylation of the insulin-like growth factor binding protein-3 gene and prognosis of epithelial ovarian cancer. Int J Gynecol Cancer 16, 210-218.
66. Petrocca, F., Iliopoulos, D., Qin, H.R., Nicoloso, M.S., Yendamuri, S., Wojcik, S.E., Shimizu, M., Di Leva, G., Vecchione, A., Trapasso, F., Godwin, A.K., Negrini, M., Calin, G.A., and Croce, C.M. (2006) Alterations of the tumor suppressor gene ARLTS1 in ovarian cancer. Cancer Res 66, 10287-10291.
67. Akahira, J., Sugihashi, Y., Suzuki, T., Ito, K., Niikura, H., Moriya, T., Nitta, M., Okamura, H., Inoue, S., Sasano, H., Okamura, K., and Yaegashi, N. (2004b) Decreased expression of 14-3-3 sigma is associated with advanced disease in human epithelial ovarian cancer: its correlation with aberrant DNA methylation. Clin Cancer Res 10, 2687-2693.
68. Mhawech, P., Benz, A., Cerato, C., Greloz, V., Assaly, M., Desmond, J.C., Koeffler, H.P., Lodygin, D., Hermeking, H., Herrmann, F., and Schwaller, J. (2005) Downregulation of 14- 3-3sigma in ovary, prostate and endometrial carcinomas is associated with CpG island methylation. Mod Pathol 18, 340-348.
69. Kaneuchi, M., Sasaki, M., Tanaka, Y., Shiina, H., Verma, M., Ebina, Y., Nomura, E., Yamamoto, R., Sakuragi, N., and Dahiya, R. (2004) Expression and methylation status of 14- 3-3 sigma gene can characterize the different histological features of ovarian cancer. Biochem Biophys Res Commun 316, 1156-1162.
70. Akahira, J., Sugihashi, Y., Ito, K., Niikura, H., Okamura, K., and Yaegashi, N. (2004a) Promoter methylation status and expression of TMS1 gene in human epithelial ovarian cancer. Cancer Sci 95, 40-43.
71. Kaneuchi, M., Sasaki, M., Tanaka, Y., Shiina, H., Yamada, H., Yamamoto, R., Sakuragi, N., Enokida, H., Verma, M., and Dahiya, R. (2005) WT1 and WT1-AS genes are inactivated by promoter methylation in ovarian clear cell adenocarcinoma. Cancer 104, 1924-1930.
72. Terasawa, K., Sagae, S., Toyota, M., Tsukada, K., Ogi, K., Satoh, A., Mita, H., Imai, K., Tokino, T., and Kudo, R. (2004) Epigenetic inactivation of TMS1/ASC in ovarian cancer. Clin Cancer Res 10, 2000-2006.
73. Chien, J., Staub, J., Avula, R., Zhang, H., Liu, W., Hartmann, L.C., Kaufmann, S.H., Smith, D.I., and Shridhar, V. (2005) Epigenetic silencing of TCEAL7 (Bex4) in ovarian cancer. Oncogene 24, 5089-5100.
74. Wang, Z., Li, M., Lu, S., Zhang, Y., and Wang, H. (2006) Promoter hypermethylation of FANCF plays an important role in the occurrence of ovarian cancer through disrupting Fanconi anemia-BRCA pathway. Cancer Biol Ther 5, 256-260.
75. Shen, D.H., Chan, K.Y., Khoo, U.S., Ngan, H.Y., Xue, W.C., Chiu, P.M., Ip, P., and Cheung, A.N. (2005) Epigenetic and genetic alterations of p33ING1b in ovarian cancer. Carcinogenesis 26, 855-863.
76. Sutherland, K.D., Lindeman, G.J., Choong, D.Y., Wittlin, S., Brentzell, L., Phillips, W., Campbell, I.G., and Visvader, J.E. (2004) Differential hypermethylation of SOCS genes in ovarian and breast carcinomas. Oncogene 23, 7726-7733.
77. Terasawa, K., Toyota, M., Sagae, S., Ogi, K., Suzuki, H., Sonoda, T., Akino, K., Maruyama, R., Nishikawa, N., Imai, K., Shinomura, Y., Saito, T., and Tokino, T. (2006) Epigenetic inactivation of TCF2 in ovarian cancer and various cancer cell lines. Br J Cancer 94, 914-921.
78. Helleman, J., van Staveren, I.L., Dinjens, W.N., van Kuijk, P.F., Ritstier, K., Ewing, P.C., van der Burg, M.E., Stoter, G., and Berns, E.M. (2006) Mismatch repair and treatment resistance in ovarian cancer. BMC Cancer 6, 201.
79. Strathdee, G., MacKean, M.J., Illand, M., and Brown, R. (1999) A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 18, 2335-2341.
80. Berger, S.L. (2002) Histone modifications in transcriptional regulation. Curr Opin Genet Dev 12, 142-148.
81. Gregory, P.D., Wagner, K., and Horz, W. (2001) Histone acetylation and chromatin remodeling. Exp Cell Res 265, 195-202.
82. Rice, J.C., and Allis, C.D. (2001) Histone methylation versus histone acetylation: new insights into epigenetic regulation. Curr Opin Cell Biol 13, 263-273.
83. Fischle, W., Wang, Y., and Allis, C.D. (2003) Histone and chromatin cross-talk. Curr Opin Cell Biol 15, 172-183.
84. Lachner, M., O'Carroll, D., Rea, S., Mechtler, K., and Jenuwein, T. (2001) Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. Nature 410, 116-120.
85. Yu, Y., Fujii, S., Yuan, J., Luo, R.Z., Wang, L., Bao, J., Kadota, M., Oshimura, M., Dent, S.R., Issa, J.P., and Bast, R.C., Jr. (2003) Epigenetic regulation of ARHI in breast and ovarian cancer cells. Ann N Y Acad Sci 983, 268-277.
86. Caslini, C., Capo-chichi, C.D., Roland, I.H., Nicolas, E., Yeung, A.T., and Xu, X.X. (2006) Histone modifications silence the GATA transcription factor genes in ovarian cancer. Oncogene 25, 5446-5461.
87. Hibbs, K., Skubitz, K.M., Pambuccian, S.E., Casey, R.C., Burleson, K.M., Oegema, T.R., Jr., Thiele, J.J., Grindle, S.M., Bliss, R.L., and Skubitz, A.P. (2004) Differential gene expression in ovarian carcinoma: identification of potential biomarkers. Am J Pathol 165, 397-414.
88. Honda, H., Pazin, M.J., Ji, H., Wernyj, R.P., and Morin, P.J. (2006) Crucial roles of Sp1 and epigenetic modifications in the regulation of the CLDN4 promoter in ovarian cancer cells. J Biol Chem 281, 21433-21444.
89. Hough, C.D., Sherman-Baust, C.A., Pizer, E.S., Montz, F.J., Im, D.D., Rosenshein, N.B., Cho, K.R., Riggins, G.J., and Morin, P.J. (2000) Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res 60, 6281-6287.
90. Lu, K.H., Patterson, A.P., Wang, L., Marquez, R.T., Atkinson, E.N., Baggerly, K.A., Ramoth, L.R., Rosen, D.G., Liu, J., Hellstrom, I., Smith, D., Hartmann, L., Fishman, D., Berchuck, A., Schmandt, R., Whitaker, R., Gershenson, D.M., Mills, G.B., and Bast, R.C., Jr. (2004) Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 10, 3291-3300.
91. Rangel, L.B., Agarwal, R., D'Souza, T., Pizer, E.S., Alo, P.L., Lancaster, W.D., Gregoire, L., Schwartz, D.R., Cho, K.R., and Morin, P.J. (2003) Tight junction proteins claudin-3 and claudin- 4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res 9, 2567-2575.
92. Zhu, Y., Brannstrom, M., Janson, P.O., and Sundfeldt, K. (2006) Differences in expression patterns of the tight junction proteins,claudin 1, 3, 4 and 5, in human ovarian surface epithelium as compared to epithelia in inclusion cysts and epithelial ovarian tumours. Int J Cancer 118, 1884-1891.
93. Cheng, P., Schmutte, C., Cofer, K.F., Felix, J.C., Yu, M.C., and Dubeau, L. (1997) Alterations in DNA methylation are early, but not initial, events in ovarian tumorigenesis. Br J Cancer 75, 396-402.
94. Rose, S.L., Fitzgerald, M.P., White, N.O., Hitchler, M.J., Futscher, B.W., De Geest, K., and Domann, F.E. (2006) Epigenetic regulation of maspin expression in human ovarian carcinoma cells. Gynecol Oncol 102, 319-324.
95. Gupta, A., Godwin, A.K., Vanderveer, L., Lu, A., and Liu, J. (2003) Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma. Cancer Res 63, 664-673.
96. Czekierdowski, A., Czekierdowska, S., Wielgos, M., Smolen, A., Kaminski, P., and Kotarski, J. (2006) The role of CpG islands hypomethylation and abnormal expression of neuronal protein synuclein-gamma (SNCG) in ovarian cancer. Neuro Endocrinol Lett 27.
97. Menendez, L., Benigno, B.B., and McDonald, J.F. (2004) L1 and HERV-W retrotransposons are hypomethylated in human ovarian carcinomas. Mol Cancer 3, 12.
98. Narayan, A., Ji, W., Zhang, X.Y., Marrogi, A., Graff, J.R., Baylin, S.B., and Ehrlich, M. (1998) Hypomethylation of pericentromeric DNA in breast adenocarcinomas. Int J Cancer 77, 833-838.
99. Qu, G., Dubeau, L., Narayan, A., Yu, M.C., and Ehrlich, M. (1999) Satellite DNA hypomethylation vs. overall genomic hypomethylation in ovarian epithelial tumors of different malignant potential. Mutat Res 423, 91-101.
100. Widschwendter, M., Jiang, G., Woods, C., Muller, H.M., Fiegl, H., Goebel, G., Marth, C., Muller-Holzner, E., Zeimet, A.G., Laird, P.W., and Ehrlich, M. (2004a) DNA hypomethylation and ovarian cancer biology. Cancer Res 64, 4472-4480.
101. Widschwendter, M., Siegmund, K.D., Muller, H.M., Fiegl, H., Marth, C., Muller-Holzner, E., Jones, P.A., and Laird, P.W. (2004b) Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res 64, 3807-3813.
102. Nishiyama, R., Qi, L., Lacey, M., and Ehrlich, M. (2005) Both hypomethylation and hypermethylation in a 0.2-kb region of a DNA repeat in cancer. Mol Cancer Res 3, 617-626.
103. Herman, J.G., Graff, J.R., Myohanen, S., Nelkin, B.D., and Baylin, S.B. (1996) Methylationspecific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93, 9821-9826.
104. Laird, P.W. (2003) The power and the promise of DNA methylation markers. Nat Rev Cancer 3, 253-266.
105. Eads, C.A., Danenberg, K.D., Kawakami, K., Saltz, L.B., Blake, C., Shibata, D., Danenberg, P.V., and Laird, P.W. (2000) MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 28, E32.
106. Rand, K.N., Ho, T., Qu, W., Mitchell, S.M., White, R., Clark, S.J., and Molloy, P.L. (2005) Headloop suppression PCR and its application to selective amplification of methylated DNA sequences. Nucleic Acids Res 33, e127.
107. Muller, H.M., Oberwalder, M., Fiegl, H., Morandell, M., Goebel, G., Zitt, M., Muhlthaler, M., Ofner, D., Margreiter, R., and Widschwendter, M. (2004) Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet 363, 1283-1285.
108. Muller, H.M., Widschwendter, A., Fiegl, H., Ivarsson, L., Goebel, G., Perkmann, E., Marth, C., and Widschwendter, M. (2003) DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res 63, 7641-7645.
109. Cottrell, S.E., and Laird, P.W. (2003) Sensitive detection of DNA methylation. Ann N Y Acad Sci 983, 120-130.
110. Hoque, M.O., Begum, S., Topaloglu, O., Jeronimo, C., Mambo, E., Westra, W.H., Califano, J.A., and Sidransky, D. (2004) Quantitative detection of promoter hypermethylation of multiple genes in the tumor, urine, and serum DNA of patients with renal cancer. Cancer Res 64, 5511-5517.
111. Hoque, M.O., Feng, Q., Toure, P., Dem, A., Critchlow, C.W., Hawes, S.E., Wood, T., Jeronimo, C., Rosenbaum, E., Stern, J., Yu, M., Trink, B., Kiviat, N.B., and Sidransky, D. (2006) Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J Clin Oncol 24, 4262-4269.
112. Leung, W.K., To, K.F., Man, E.P., Chan, M.W., Bai, A.H., Hui, A.J., Chan, F.K., and Sung, J.J. (2005) Quantitative detection of promoter hypermethylation in multiple genes in the serum of patients with colorectal cancer. Am J Gastroenterol 100, 2274-2279.
113. Chan, M.W., Wei, S.H., Wen, P., Wang, Z., Matei, D.E., Liu, J.C., Liyanarachchi, S., Brown, R., Nephew, K.P., Yan, P.S., and Huang, T.H. (2005) Hypermethylation of 18S and 28S ribosomal DNAs predicts progression-free survival in patients with ovarian cancer. Clin Cancer Res 11, 7376-7383.
114. Huang, T.H., Perry, M.R., and Laux, D.E. (1999) Methylation profiling of CpG islands in human breast cancer cells. Hum Mol Genet 8, 459-470.
115. Wei, S.H., Chen, C.M., Strathdee, G., Harnsomburana, J., Shyu, C.R., Rahmatpanah, F., Shi, H., Ng, S.W., Yan, P.S., Nephew, K.P., Brown, R., and Huang, T.H. (2002) Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res 8, 2246-2252.
116. Wei, S.H., Balch, C., Paik, H.H., Kim, Y.S., Baldwin, R.L., Liyanarachchi, S., Li, L., Wang, Z., Wan, J.C., Davuluri, R.V., Karlan, B.Y., Gifford, G., Brown, R., Kim, S., Huang, T.H., and Nephew, K.P. (2006) Prognostic DNA methylation biomarkers in ovarian cancer. Clin Cancer Res 12, 2788-2794.
117. Balch, C., Huang, T.H., Brown, R., and Nephew, K.P. (2004) The epigenetics of ovarian cancer drug resistance and resensitization. Am J Obstet Gynecol 191, 1552-1572.
118. Teodoridis, J.M., Strathdee, G., and Brown, R. (2004) Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker. Drug Resist Updat 7, 267-278.
119. Wei, S.H., Brown, R., and Huang, T.H. (2003) Aberrant DNA methylation in ovarian cancer: is there an epigenetic predisposition to drug response? Ann N Y Acad Sci 983, 243-250.
120. Brown, R., Hirst, G.L., Gallagher, W.M., McIlwrath, A.J., Margison, G.P., van der Zee, A.G., and Anthoney, D.A. (1997) hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene 15, 45-52.
121. Plumb, J.A., Strathdee, G., Sludden, J., Kaye, S.B., and Brown, R. (2000) Reversal of drug resistance in human tumor xenografts by 2 -deoxy-5- azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 60, 6039-6044.
122. Gifford, G., Paul, J., Vasey, P.A., Kaye, S.B., and Brown, R. (2004) The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin Cancer Res 10, 4420-4426.
123. Taniguchi, T., Tischkowitz, M., Ameziane, N., Hodgson, S.V., Mathew, C.G., Joenje, H., Mok, S.C., and D'Andrea, A.D. (2003) Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 9, 568-574.
124. Shridhar, V., Bible, K.C., Staub, J., Avula, R., Lee, Y.K., Kalli, K., Huang, H., Hartmann, L.C., Kaufmann, S.H., and Smith, D.I. (2001) Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer. Cancer Res 61, 4258-4265.
125. Strathdee, G., Davies, B.R., Vass, J.K., Siddiqui, N., and Brown, R. (2004) Cell type-specific methylation of an intronic CpG island controls expression of the MCJ gene. Carcinogenesis 25, 693-701.
126. Strathdee, G., Vass, J.K., Oien, K.A., Siddiqui, N., Curto-Garcia, J., and Brown, R. (2005) Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy. Gynecol Oncol 97, 898-903.
127. Hickey, K.P., Boyle, K.P., Jepps, H.M., Andrew, A.C., Buxton, E.J., and Burns, P.A. (1999) Molecular detection of tumour DNA in serum and peritoneal fluid from ovarian cancer patients. Br J Cancer 80, 1803-1808.
128. Lee, W.H., Morton, R.A., Epstein, J.I., Brooks, J.D., Campbell, P.A., Bova, G.S., Hsieh, W.S., Isaacs, W.B., and Nelson, W.G. (1994) Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA 91, 11733-11737.
129. Song, J.Z., Stirzaker, C., Harrison, J., Melki, J.R., and Clark, S.J. (2002) Hypermethylation trigger of the glutathione-S-transferase gene (GSTP1) in prostate cancer cells. Oncogene 21, 1048-1061.
130. Ushijima, T. (2005) Detection and interpretation of altered methylation patterns in cancer cells. Nat Rev Cancer 5, 223-231.
131. Jones, P.A., and Martienssen, R. (2005) A blueprint for a Human Epigenome Project: the AACR Human Epigenome Workshop. Cancer Res 65, 11241-11246.
132. Frigola, J., Song, J., Stirzaker, C., Hinshelwood, R.A., Peinado, M.A., and Clark, S.J. (2006) Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band. Nat Genet 38, 540-549.
133. Yoo, C.B., and Jones, P.A. (2006) Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov 5, 37-50.